UK Generics Market Analysis
Single User PDF Format: US$ 800.00
Multi-User License: US$ 1,100.00
Hard Copy: US$ 900.00
CD-ROM: US$ 900.00
The UK is one of the largest economies in the world. The per capita income and spending has been also increasing for the last few years. Besides, due to the increasing consumer spending on the branded products, the healthcare spending in the UK is increasing. However, the government has saved up to GBP 7 Billion (US$ 11.3 Billion) annually by using generics. Due to this, the government of UK has been promoting the usage of generics in the country, which has fuelled the growth of generics market in the country.
As per our new report “UK Generics Market Analysis”, the generics market is anticipated to grow at a CAGR of around 16% during 2011-2013. Majorly, growth of the market will be fuelled by the patent expirations of various blockbuster drugs during the next 2-3 years. This will result in the launch of more generics product of the drugs. Besides, entry of several global generics manufacturers in the country has boosted the demand for generics.
Moreover, our report provides segmentation of generics product on the basis of prescriptions. Generic drugs accounted for around 86% of the total prescriptions written in 2009. The major reason for such a huge share is that, the pharmacists in the UK are reimbursed a certain percentage of the selling price of the medicine, though it has a fixed rate of reimbursement. This share is further anticipated to increase in future on the back of strong government support.
"UK Generics Market Analysis" has properly segmented the market on the basis of value, number of prescriptions written off, and therapeutics. It also provides information on the key competitors in the market along with their business information. The report shows a highly concentrated structure of the market, with the top players dominating the market. It also provides segment level analysis of the industry along with the emerging trends that may shape up with the betterment of economic conditions.
The research will help consultants, industry analysts, and vendors to get in-depth knowledge of the current, past, and future performance of the industry. The report provides an extensive research on the recent trends of the UK generics industry along with impartial analysis considering the impact of financial crisis on its performance.
Multi-User License: US$ 1,100.00
Hard Copy: US$ 900.00
CD-ROM: US$ 900.00
The UK is one of the largest economies in the world. The per capita income and spending has been also increasing for the last few years. Besides, due to the increasing consumer spending on the branded products, the healthcare spending in the UK is increasing. However, the government has saved up to GBP 7 Billion (US$ 11.3 Billion) annually by using generics. Due to this, the government of UK has been promoting the usage of generics in the country, which has fuelled the growth of generics market in the country.
As per our new report “UK Generics Market Analysis”, the generics market is anticipated to grow at a CAGR of around 16% during 2011-2013. Majorly, growth of the market will be fuelled by the patent expirations of various blockbuster drugs during the next 2-3 years. This will result in the launch of more generics product of the drugs. Besides, entry of several global generics manufacturers in the country has boosted the demand for generics.
Moreover, our report provides segmentation of generics product on the basis of prescriptions. Generic drugs accounted for around 86% of the total prescriptions written in 2009. The major reason for such a huge share is that, the pharmacists in the UK are reimbursed a certain percentage of the selling price of the medicine, though it has a fixed rate of reimbursement. This share is further anticipated to increase in future on the back of strong government support.
"UK Generics Market Analysis" has properly segmented the market on the basis of value, number of prescriptions written off, and therapeutics. It also provides information on the key competitors in the market along with their business information. The report shows a highly concentrated structure of the market, with the top players dominating the market. It also provides segment level analysis of the industry along with the emerging trends that may shape up with the betterment of economic conditions.
The research will help consultants, industry analysts, and vendors to get in-depth knowledge of the current, past, and future performance of the industry. The report provides an extensive research on the recent trends of the UK generics industry along with impartial analysis considering the impact of financial crisis on its performance.
1. ANALYST VIEW
2. RESEARCH METHODOLOGY
3. MARKET OVERVIEW
4. MARKET DRIVERS
4.1 Aging Population
4.2 BigPharmas: The New Market Entrants
4.3 Generics Lowering NHS Budget
4.4 Patent Expiration: Paving the Way for Generics
5. INDUSTRY PERFORMANCE
5.1 By Value
5.2 By Prescription
5.3 By Therapeutics
5.3.1 Cardiovascular
5.3.2 Endocrine & Metabolic Agents
5.3.3 Respiratory Agents
5.3.4 Analgesics
5.3.5 Gastrointestinal
6. REGULATORY FRAMEWORK
7. POTENTIAL GROWTH AREAS
7.1 Biosimilars
7.2 Personalized Generics
7.3 Injectable Generics
8. COMPETITIVE LANDSCAPE
8.1 Teva Pharmaceutical
8.2 Sandoz
8.3 Actavis UK Ltd.
8.4 Hikma Pharmaceuticals
2. RESEARCH METHODOLOGY
3. MARKET OVERVIEW
4. MARKET DRIVERS
4.1 Aging Population
4.2 BigPharmas: The New Market Entrants
4.3 Generics Lowering NHS Budget
4.4 Patent Expiration: Paving the Way for Generics
5. INDUSTRY PERFORMANCE
5.1 By Value
5.2 By Prescription
5.3 By Therapeutics
5.3.1 Cardiovascular
5.3.2 Endocrine & Metabolic Agents
5.3.3 Respiratory Agents
5.3.4 Analgesics
5.3.5 Gastrointestinal
6. REGULATORY FRAMEWORK
7. POTENTIAL GROWTH AREAS
7.1 Biosimilars
7.2 Personalized Generics
7.3 Injectable Generics
8. COMPETITIVE LANDSCAPE
8.1 Teva Pharmaceutical
8.2 Sandoz
8.3 Actavis UK Ltd.
8.4 Hikma Pharmaceuticals
LIST OF FIGURES:
Figure 3-1: Pharmaceutical Market (Billion GBP), 2009 & 2010
Figure 3-2: Forecast for Pharmaceutical Market (Billion GBP), 2011-2013
Figure 3-3: Share of Generics in Pharma Market (%), 2010
Figure 3-4: Forecast for Share of Generics in Pharma Market (%), 2013
Figure 4-1: Population Aged 65 and Above (Million), 2009-2013
Figure 5-1: Generics Market (Billion GBP), 2009-2013
Figure 5-2: Total Number of Prescriptions (Million), 2009-2013
Figure 5-3: Net Ingredient Cost of Prescriptions (Million GBP), 2005-2009
Figure 5-4: Share of Generics Prescriptions in Total Prescriptions (2009)
Figure 5-5: Analgesics Market (Million GBP), 2010 & 2013
Figure 3-1: Pharmaceutical Market (Billion GBP), 2009 & 2010
Figure 3-2: Forecast for Pharmaceutical Market (Billion GBP), 2011-2013
Figure 3-3: Share of Generics in Pharma Market (%), 2010
Figure 3-4: Forecast for Share of Generics in Pharma Market (%), 2013
Figure 4-1: Population Aged 65 and Above (Million), 2009-2013
Figure 5-1: Generics Market (Billion GBP), 2009-2013
Figure 5-2: Total Number of Prescriptions (Million), 2009-2013
Figure 5-3: Net Ingredient Cost of Prescriptions (Million GBP), 2005-2009
Figure 5-4: Share of Generics Prescriptions in Total Prescriptions (2009)
Figure 5-5: Analgesics Market (Million GBP), 2010 & 2013
LIST OF TABLES:
Table 3-1: Healthcare Statistics (2008-2010)
Table 3-2: Forecast for Healthcare Statistics (2011-2013)
Table 4-1: Blockbuster Drugs Going Off-patent (2011-2013)
Table 5-1: Top 10 Most Prescribed Generic Drugs (Million), 2010
Table 7-1: Currently Approved Biosimilar Products in EU
Table 8-1: Teva Pharmaceuticals - SWOT Analysis
Table 8-2: Sandoz - SWOT Analysis
Table 8-3: Actavis UK Ltd. - SWOT Analysis
Table 8-4: Hikma Pharmaceuticals - SWOT Analysis
Table 3-1: Healthcare Statistics (2008-2010)
Table 3-2: Forecast for Healthcare Statistics (2011-2013)
Table 4-1: Blockbuster Drugs Going Off-patent (2011-2013)
Table 5-1: Top 10 Most Prescribed Generic Drugs (Million), 2010
Table 7-1: Currently Approved Biosimilar Products in EU
Table 8-1: Teva Pharmaceuticals - SWOT Analysis
Table 8-2: Sandoz - SWOT Analysis
Table 8-3: Actavis UK Ltd. - SWOT Analysis
Table 8-4: Hikma Pharmaceuticals - SWOT Analysis
